董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey S. Hatfield | 男 | Board Chair | 68 | 18.46万美元 | 13.17 | 2026-05-26 |
| Robert More | 男 | Independent Director | 58 | 18.29万美元 | 62.92 | 2026-05-26 |
| Norbert Bischofberger | 男 | Independent Director | 70 | 17.67万美元 | 6.40 | 2026-05-26 |
| Janet Napolitano | 女 | Independent Director | 68 | 16.00万美元 | 10.32 | 2026-05-26 |
| Ramy Farid | 男 | Independent Director | 61 | 16.50万美元 | 6.40 | 2026-05-26 |
| Marianne De Backer | -- | President, Chief Executive Officer and Director | 57 | 783.40万美元 | 161.28 | 2026-05-26 |
| Elliott Sigal | 男 | Independent Director | 74 | 18.75万美元 | 12.78 | 2026-05-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Eisner | 男 | Executive Vice President and Chief Medical Officer | 61 | 237.15万美元 | 未持股 | 2026-05-26 |
| Vanina de Verneuil | 女 | Executive Vice President, General Counsel and Corporate Secretary | 47 | 169.08万美元 | 17.35 | 2026-05-26 |
| Marianne De Backer | -- | President, Chief Executive Officer and Director | 57 | 783.40万美元 | 161.28 | 2026-05-26 |
| Jason O byrne | 男 | Executive Vice President and Chief Financial Officer | 57 | 195.18万美元 | 10.26 | 2026-05-26 |
董事简历
中英对照 | 中文 | 英文- Jeffrey S. Hatfield
-
Jeffrey S. Hatfield从2004年3月开始担任总裁、首席执行官与我司董事。加入Vitae前，Hatfield先生在百时美施贵宝公司（Bristol-Myers Squibb）任职，这是一家大型上市生物制药公司，他于1985年加入该公司，担任多个执行职位，包括：从2000年到2004年，担任百时美施贵宝公司的病毒学与免疫学部门的高级副总裁；从1997年到2000年，担任加拿大部的总裁兼总经理；从1996年到1997年，担任美国管理医疗保健部的副总裁。Hatfield先生于2014年担任Ambit Biosciences董事这是一家生物医药公司。Hatfield先生在宾夕法尼亚大学（University of Pennsylvania）沃顿商学院获得工商管理硕士学位，并在珀杜大学（Purdue University）获得配药学学士学位。
Jeffrey S. Hatfield is a veteran biotechnology and pharmaceutical industry leader, with over three decades of experience. Mr. Hatfield is currently the chief executive officer of Zafgen, Inc. Previously, he served as president and chief executive officer of Vitae Pharmaceuticals, Inc., from March 2004 until its acquisition by Allergan in 2016. Prior to working at Vitae Pharmaceuticals, Inc., Mr. Hatfield served in numerous executive capacities at Bristol-Myers Squibb Company, or BMS, including senior vice president of BMS's Immunology and Virology divisions, president of BMS Canada,and head of U.S. market access. Mr. Hatfield currently serves as a director on the boards of publicly traded biotechnology companies aTyr Pharma, Inc. since April 2017 and Zafgen, Inc. since October 2017 and has previously served as a director of Ambit Biosciences Corporation, prior to its acquisition by Daiichi Sankyo Company, Ltd. in 2015 InVivo Therapeutics, Inc. from October 2016 to December 2018 and Vitae Pharmaceuticals, Inc., prior to its acquisition by Allergan plc in 2016. He is an adjunct professor and a dean's advisory board member for Purdue University's College of Pharmacy and is a Key Advisory Board member for the Harvard Business School's Blavatnik Fellowship in Life Sciences Entrepreneurship. He earned a B.S. degree in pharmacy from Purdue University's College of Pharmacy and an M.B.A. degree from The Wharton School at the University of Pennsylvania. - Jeffrey S. Hatfield从2004年3月开始担任总裁、首席执行官与我司董事。加入Vitae前，Hatfield先生在百时美施贵宝公司（Bristol-Myers Squibb）任职，这是一家大型上市生物制药公司，他于1985年加入该公司，担任多个执行职位，包括：从2000年到2004年，担任百时美施贵宝公司的病毒学与免疫学部门的高级副总裁；从1997年到2000年，担任加拿大部的总裁兼总经理；从1996年到1997年，担任美国管理医疗保健部的副总裁。Hatfield先生于2014年担任Ambit Biosciences董事这是一家生物医药公司。Hatfield先生在宾夕法尼亚大学（University of Pennsylvania）沃顿商学院获得工商管理硕士学位，并在珀杜大学（Purdue University）获得配药学学士学位。
- Jeffrey S. Hatfield is a veteran biotechnology and pharmaceutical industry leader, with over three decades of experience. Mr. Hatfield is currently the chief executive officer of Zafgen, Inc. Previously, he served as president and chief executive officer of Vitae Pharmaceuticals, Inc., from March 2004 until its acquisition by Allergan in 2016. Prior to working at Vitae Pharmaceuticals, Inc., Mr. Hatfield served in numerous executive capacities at Bristol-Myers Squibb Company, or BMS, including senior vice president of BMS's Immunology and Virology divisions, president of BMS Canada,and head of U.S. market access. Mr. Hatfield currently serves as a director on the boards of publicly traded biotechnology companies aTyr Pharma, Inc. since April 2017 and Zafgen, Inc. since October 2017 and has previously served as a director of Ambit Biosciences Corporation, prior to its acquisition by Daiichi Sankyo Company, Ltd. in 2015 InVivo Therapeutics, Inc. from October 2016 to December 2018 and Vitae Pharmaceuticals, Inc., prior to its acquisition by Allergan plc in 2016. He is an adjunct professor and a dean's advisory board member for Purdue University's College of Pharmacy and is a Key Advisory Board member for the Harvard Business School's Blavatnik Fellowship in Life Sciences Entrepreneurship. He earned a B.S. degree in pharmacy from Purdue University's College of Pharmacy and an M.B.A. degree from The Wharton School at the University of Pennsylvania.
- Robert More
-
Robert More自2016年9月以来一直担任我们的董事会成员。自2016年10月以来，More先生一直担任风险投资公司Alta Partners的董事总经理。从2013年7月到2015年5月，More先生担任比尔与梅琳达·盖茨基金会（Bill&Melinda Gates Foundation）的高级顾问，并领导其全球健康创业计划。2008年9月至2013年6月和1996年6月至2008年7月，他分别担任风险投资公司Frazier梦百合Ventures和Domain Associates的普通合伙人。More先生目前担任SiennaBiopharmaceuticals，Inc.公司（一家公共制药公司）的董事会成员。他目前也任职于以下私人公司的董事会:生物技术公司AffiniVax，Inc.、生物技术公司eGenesis、生物技术公司Qihan Biotech、生物技术公司Sirenas，LLC、生物技术公司Tyra Biosciences，Inc.，并担任Liquiglide，Inc.（生物技术公司）的顾问。莫尔曾担任以下上市公司的董事会成员:生物制药公司Achaogen，Inc.、医疗设备公司Carticept Medical，Inc.、医疗设备公司Cartiva、制药公司Neothetics Inc.、医疗技术公司Glaukos Corporation和IntraLase Corp.，2007年被Advanced Medical Optics收购的医疗器械公司。他此前也曾任职于以下生命科学公司的董事会:ESP Pharma，Inc.、Proxima Therapeutics，Inc.、Novacardia，Inc.、Esprit Pharma，Inc.和Oceana Therapeutics，Inc.。More先生是考夫曼研究员计划（Kauffman Fellows Program）的董事会创始成员，之前曾在One Revolution和Foundation for Innovative New Diagnostics Find的董事会任职。More先生目前在生物技术创新组织（BIO）的理事会之一任职。他在Middlebury College获得生物学学士学位，在University of Virginia的Darden工商管理学院获得工商管理硕士学位。
Robert More,Managing Director, Alta Partners (2016 – 2025),Senior Advisor, Bill & Melinda Gates Foundation (2013– 2015),General Partner, Frazier Healthcare Ventures (2008 – 2013),General Partner, Domain Associates (1996 – 2008),B.S., Biology, Middlebury College,MBA, Darden School of Business Administration at the University of Virginia. - Robert More自2016年9月以来一直担任我们的董事会成员。自2016年10月以来，More先生一直担任风险投资公司Alta Partners的董事总经理。从2013年7月到2015年5月，More先生担任比尔与梅琳达·盖茨基金会（Bill&Melinda Gates Foundation）的高级顾问，并领导其全球健康创业计划。2008年9月至2013年6月和1996年6月至2008年7月，他分别担任风险投资公司Frazier梦百合Ventures和Domain Associates的普通合伙人。More先生目前担任SiennaBiopharmaceuticals，Inc.公司（一家公共制药公司）的董事会成员。他目前也任职于以下私人公司的董事会:生物技术公司AffiniVax，Inc.、生物技术公司eGenesis、生物技术公司Qihan Biotech、生物技术公司Sirenas，LLC、生物技术公司Tyra Biosciences，Inc.，并担任Liquiglide，Inc.（生物技术公司）的顾问。莫尔曾担任以下上市公司的董事会成员:生物制药公司Achaogen，Inc.、医疗设备公司Carticept Medical，Inc.、医疗设备公司Cartiva、制药公司Neothetics Inc.、医疗技术公司Glaukos Corporation和IntraLase Corp.，2007年被Advanced Medical Optics收购的医疗器械公司。他此前也曾任职于以下生命科学公司的董事会:ESP Pharma，Inc.、Proxima Therapeutics，Inc.、Novacardia，Inc.、Esprit Pharma，Inc.和Oceana Therapeutics，Inc.。More先生是考夫曼研究员计划（Kauffman Fellows Program）的董事会创始成员，之前曾在One Revolution和Foundation for Innovative New Diagnostics Find的董事会任职。More先生目前在生物技术创新组织（BIO）的理事会之一任职。他在Middlebury College获得生物学学士学位，在University of Virginia的Darden工商管理学院获得工商管理硕士学位。
- Robert More,Managing Director, Alta Partners (2016 – 2025),Senior Advisor, Bill & Melinda Gates Foundation (2013– 2015),General Partner, Frazier Healthcare Ventures (2008 – 2013),General Partner, Domain Associates (1996 – 2008),B.S., Biology, Middlebury College,MBA, Darden School of Business Administration at the University of Virginia.
- Norbert Bischofberger
-
Norbert Bischofberger自2018年8月起担任我们的总裁兼首席执行官，自2018年4月起担任我们的董事会成员，并于2020年7月至2020年8月担任我们的代理首席财务官。1990年8月至2018年8月，Bischofberger博士曾在生物制药公司吉利德科学公司担任多个职位，最近担任吉利德执行Vice President，研究与开发和首席科学官。任职Gilead公司28年期间，他曾主持超过25种治疗一系列严重疾病的疗法产品的开发和批准。在加入Gilead之前，Bischofberger博士从1986年到1990年担任生物技术公司Genentech，Inc.DNA合成组的高级科学家。Bischofberger博士在拜耳公司（Bayer AG）的监事会和Morphic Therapeutic公司（一家公共生物制药公司）的董事会任职。Bischofberger博士在瑞士苏黎世的Eidgenosische Technische Hochschule获得有机化学博士学位，并在因斯布鲁克大学（University of Innsbruck）获得化学硕士学位。
Norbert Bischofberger has served as our President and Chief Executive Officer since August 2018 as a member of our board of directors since April 2018 and as our acting principal financial officer from July 2020 to August 2020. From August 1990 to August 2018 Dr. Bischofberger held various positions at Gilead Sciences, Inc., a biopharmaceutical company, and most recently served Gilead as Executive Vice President, Research and Development and Chief Scientific Officer. During his 28-year tenure at Gilead, he presided over the development and approval of more than 25 therapeutics products for a range of serious conditions. Prior to Gilead, Dr. Bischofberger served as a Senior Scientist in the DNA Synthesis group at Genentech, Inc., a biotechnology company, from 1986 to 1990. Dr. Bischofberger serves on the Supervisory Board of Bayer AG and board of directors of Morphic Therapeutic, a public biopharmaceutical company. Dr. Bischofberger received a Ph.D. in Organic Chemistry from the Eidgenossische Technische Hochschule in Zurich, Switzerland and an M.S. in Chemistry from the University of Innsbruck. - Norbert Bischofberger自2018年8月起担任我们的总裁兼首席执行官，自2018年4月起担任我们的董事会成员，并于2020年7月至2020年8月担任我们的代理首席财务官。1990年8月至2018年8月，Bischofberger博士曾在生物制药公司吉利德科学公司担任多个职位，最近担任吉利德执行Vice President，研究与开发和首席科学官。任职Gilead公司28年期间，他曾主持超过25种治疗一系列严重疾病的疗法产品的开发和批准。在加入Gilead之前，Bischofberger博士从1986年到1990年担任生物技术公司Genentech，Inc.DNA合成组的高级科学家。Bischofberger博士在拜耳公司（Bayer AG）的监事会和Morphic Therapeutic公司（一家公共生物制药公司）的董事会任职。Bischofberger博士在瑞士苏黎世的Eidgenosische Technische Hochschule获得有机化学博士学位，并在因斯布鲁克大学（University of Innsbruck）获得化学硕士学位。
- Norbert Bischofberger has served as our President and Chief Executive Officer since August 2018 as a member of our board of directors since April 2018 and as our acting principal financial officer from July 2020 to August 2020. From August 1990 to August 2018 Dr. Bischofberger held various positions at Gilead Sciences, Inc., a biopharmaceutical company, and most recently served Gilead as Executive Vice President, Research and Development and Chief Scientific Officer. During his 28-year tenure at Gilead, he presided over the development and approval of more than 25 therapeutics products for a range of serious conditions. Prior to Gilead, Dr. Bischofberger served as a Senior Scientist in the DNA Synthesis group at Genentech, Inc., a biotechnology company, from 1986 to 1990. Dr. Bischofberger serves on the Supervisory Board of Bayer AG and board of directors of Morphic Therapeutic, a public biopharmaceutical company. Dr. Bischofberger received a Ph.D. in Organic Chemistry from the Eidgenossische Technische Hochschule in Zurich, Switzerland and an M.S. in Chemistry from the University of Innsbruck.
- Janet Napolitano
-
Janet Napolitano，自2020年11月起担任Zoom Video Communications, Inc.董事会成员。Napolitano女士是加州大学伯克利分校Goldman公共政策学院的教授。此前，她曾于2013年9月担任加州大学校长，直至2020年8月离任。在担任加州大学校长之前，她曾于2009年至2013年担任美国国土安全部部长，2003年至2009年担任亚利桑那州州长，1998年至2003年担任亚利桑那州司法部长，1993年至1997年担任美国亚利桑那州地区检察官。Napolitano女士目前在Vir Biotechnology, Inc.的董事会任职，Vir Biotechnology, Inc.是一家临床阶段的免疫学公司。Napolitano女士拥有Santa Clara大学政治学学士学位和Virginia大学法学院法学博士学位。
Janet Napolitano has served as a member of the Board of Directors since November 2024. Ms. Napolitano currently serves as the founder and faculty director of the Center for Security in Politics at UC Berkeley and as a professor of public policy at the Goldman School of Public Policy at UC Berkeley. She previously served as President of the University of California from September 2013 until her departure in August 2020. Prior to her time serving as the President of the University of California, she served as the U.S. Secretary of Homeland Security from 2009 to 2013, as governor of the state of Arizona from 2003 to 2009, as attorney general of Arizona from 1998 to 2003 and as U.S. attorney for the District of Arizona from 1993 to 1997. Prior to that, Ms. Napolitano was previously a partner of Lewis and Roca LLP, a law firm, from 1989 to 1993. Ms. Napolitano currently serves on the boards of directors for Vir Biotechnology, Inc., a pharmaceutical company that developed and sold drugs, and Zoom Communications, Inc., a communications technology company, and on the board of trustees at RAND Corporation, a nonprofit global policy research institute. Ms. Napolitano holds a B.S. in political science from Santa Clara University and a J.D. from the University of Virginia School of Law. - Janet Napolitano，自2020年11月起担任Zoom Video Communications, Inc.董事会成员。Napolitano女士是加州大学伯克利分校Goldman公共政策学院的教授。此前，她曾于2013年9月担任加州大学校长，直至2020年8月离任。在担任加州大学校长之前，她曾于2009年至2013年担任美国国土安全部部长，2003年至2009年担任亚利桑那州州长，1998年至2003年担任亚利桑那州司法部长，1993年至1997年担任美国亚利桑那州地区检察官。Napolitano女士目前在Vir Biotechnology, Inc.的董事会任职，Vir Biotechnology, Inc.是一家临床阶段的免疫学公司。Napolitano女士拥有Santa Clara大学政治学学士学位和Virginia大学法学院法学博士学位。
- Janet Napolitano has served as a member of the Board of Directors since November 2024. Ms. Napolitano currently serves as the founder and faculty director of the Center for Security in Politics at UC Berkeley and as a professor of public policy at the Goldman School of Public Policy at UC Berkeley. She previously served as President of the University of California from September 2013 until her departure in August 2020. Prior to her time serving as the President of the University of California, she served as the U.S. Secretary of Homeland Security from 2009 to 2013, as governor of the state of Arizona from 2003 to 2009, as attorney general of Arizona from 1998 to 2003 and as U.S. attorney for the District of Arizona from 1993 to 1997. Prior to that, Ms. Napolitano was previously a partner of Lewis and Roca LLP, a law firm, from 1989 to 1993. Ms. Napolitano currently serves on the boards of directors for Vir Biotechnology, Inc., a pharmaceutical company that developed and sold drugs, and Zoom Communications, Inc., a communications technology company, and on the board of trustees at RAND Corporation, a nonprofit global policy research institute. Ms. Napolitano holds a B.S. in political science from Santa Clara University and a J.D. from the University of Virginia School of Law.
- Ramy Farid
-
Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior t joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and structure-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology. - Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
- Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior t joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and structure-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology.
- Marianne De Backer
-
Marianne De Backer，Vir Biotechnology, Inc.总裁兼首席执行官（2023 –至今），执行委员会，以及执行副总裁兼制药部门战略、业务发展和许可全球主管（2019 – 2023），拜耳公司，多个职责日益增加的职位，包括制药集团并购运营和资产剥离副总裁以及传染病和疫苗业务发展主管，强生（1991 – 2019），在欧洲领导商业业务部门以及在欧洲和美国从事药物发现研究的额外经验。布鲁塞尔自由大学分子生物学硕士，根特大学工程和生物化学硕士，根特大学生物技术博士，MBA，鹿特丹伊拉斯谟大学。
Marianne De Backer,President and Chief Executive Officer, Vir Biotechnology, Inc. (2023 – Present),Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing, Pharmaceuticals Division, Bayer AG (2019 – 2023),Various positions of increasing responsibility, including Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and Head of Infectious Diseases & Vaccines Business Development, Johnson & Johnson (1991 – 2019),Additional experience leading commercial business unit in Europe, as well as drug discovery research in both Europe and the United States.M.Sc., Molecular Biology, Vrije Universiteit Brussel,M.Sc., Engineering and Biochemistry, Ghent University,Ph.D., Biotechnology, Ghent University,MBA, Erasmus University Rotterdam. - Marianne De Backer，Vir Biotechnology, Inc.总裁兼首席执行官（2023 –至今），执行委员会，以及执行副总裁兼制药部门战略、业务发展和许可全球主管（2019 – 2023），拜耳公司，多个职责日益增加的职位，包括制药集团并购运营和资产剥离副总裁以及传染病和疫苗业务发展主管，强生（1991 – 2019），在欧洲领导商业业务部门以及在欧洲和美国从事药物发现研究的额外经验。布鲁塞尔自由大学分子生物学硕士，根特大学工程和生物化学硕士，根特大学生物技术博士，MBA，鹿特丹伊拉斯谟大学。
- Marianne De Backer,President and Chief Executive Officer, Vir Biotechnology, Inc. (2023 – Present),Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing, Pharmaceuticals Division, Bayer AG (2019 – 2023),Various positions of increasing responsibility, including Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and Head of Infectious Diseases & Vaccines Business Development, Johnson & Johnson (1991 – 2019),Additional experience leading commercial business unit in Europe, as well as drug discovery research in both Europe and the United States.M.Sc., Molecular Biology, Vrije Universiteit Brussel,M.Sc., Engineering and Biochemistry, Ghent University,Ph.D., Biotechnology, Ghent University,MBA, Erasmus University Rotterdam.
- Elliott Sigal
-
Elliott Sigal，是百时美施贵宝公司的前执行副总裁兼董事。他于1997年加入BMS，并在研究和发展领域担任有越来越多的责任的工作。他自2004年至2013年退休担任BMS首席研发官和研发总裁。他担任于2011年BMS董事，直到2013年退休。他曾从2002年到2011年担任普林斯顿医疗系统委员会委员。他目前担任新企业协会高级顾问的企业集团医疗团队顾问，是各种生物技术公司顾问。此外，他担任Spark Therapeutics公司的董事，也担任民间非营利基金会，黑色素瘤研究联盟的董事会成员。
Elliott Sigal served as Chief Scientific Officer of Bristol Myers Squibb, or BMS, a global biopharmaceutical company, from October 2004 to June 2013 and as a member of the BMS board of directors from March 2011 to June 2013. Dr. Sigal joined BMS in 1997 and held positions of increasing responsibility in drug discovery and development and was a member of the executive committee from September 2001 through June 2013. Prior to BMS, Dr. Sigal was Vice President of R&D and Chief Executive Officer for the genomics firm Mercator Genetics Inc. He served as a senior advisor to the healthcare team of New Enterprise Associates, a venture capital firm, from 2014 to 2023. Dr. Sigal currently serves as co chair of the Scientific Advisory Board for Amgen, Inc. Dr. Sigal also serves as a director of Vir Biotechnology, Inc. and formerly served as a director of Adaptimmune Therapeutics plc and Surface Oncology Inc. - Elliott Sigal，是百时美施贵宝公司的前执行副总裁兼董事。他于1997年加入BMS，并在研究和发展领域担任有越来越多的责任的工作。他自2004年至2013年退休担任BMS首席研发官和研发总裁。他担任于2011年BMS董事，直到2013年退休。他曾从2002年到2011年担任普林斯顿医疗系统委员会委员。他目前担任新企业协会高级顾问的企业集团医疗团队顾问，是各种生物技术公司顾问。此外，他担任Spark Therapeutics公司的董事，也担任民间非营利基金会，黑色素瘤研究联盟的董事会成员。
- Elliott Sigal served as Chief Scientific Officer of Bristol Myers Squibb, or BMS, a global biopharmaceutical company, from October 2004 to June 2013 and as a member of the BMS board of directors from March 2011 to June 2013. Dr. Sigal joined BMS in 1997 and held positions of increasing responsibility in drug discovery and development and was a member of the executive committee from September 2001 through June 2013. Prior to BMS, Dr. Sigal was Vice President of R&D and Chief Executive Officer for the genomics firm Mercator Genetics Inc. He served as a senior advisor to the healthcare team of New Enterprise Associates, a venture capital firm, from 2014 to 2023. Dr. Sigal currently serves as co chair of the Scientific Advisory Board for Amgen, Inc. Dr. Sigal also serves as a director of Vir Biotechnology, Inc. and formerly served as a director of Adaptimmune Therapeutics plc and Surface Oncology Inc.
高管简历
中英对照 | 中文 | 英文- Mark Eisner
Mark Eisner于2023年9月至2024年6月在私营临床阶段生物技术公司Sonoma Biotherapeutics，Inc.担任首席医疗官，领导所有开发职能，包括生物识别、监管、临床科学、临床运营、药物安全和药理学。2020年至2023年9月，他在生物制药公司珐博进公司（nka Kyntra Bio，Inc.）（纳斯达克：KYNB）担任执行副总裁兼首席医疗官，领导所有开发职能，包括担任中国临床开发和临床运营主管。在加入珐博进之前，Eisner博士在罗氏集团成员基因泰克工作了近11年，担任的职位责任越来越大，包括2018年至2020年的高级副总裁、免疫学、感染病和眼科产品开发全球主管，并负责许多产品的后期临床开发。在进入工业之前，艾斯纳博士是加州大学旧金山分校的医学和麻醉学教授。艾斯纳博士在斯坦福大学完成了人类生物学的A.B.学位，并在宾夕法尼亚大学医学院完成了医学博士学位。他还拥有加州大学伯克利分校公共卫生学院流行病学硕士学位。
Mark Eisner served as Chief Medical Officer at Sonoma Biotherapeutics, Inc., a private clinical stage biotechnology company, from September 2023 to June 2024, where he led all development functions, which included Biometrics, Regulatory, Clinical Science, Clinical Operations, Drug Safety and Pharmacology. From 2020 to September 2023, he served as Executive Vice President, Chief Medical Officer at FibroGen, Inc. (nka Kyntra Bio, Inc.) (Nasdaq: KYNB), a biopharmaceutical company, where he led all development functions, which included being the Head of China Clinical Development and Clinical Operations. Prior to FibroGen, Dr. Eisner spent nearly 11 years at Genentech, Inc., a member of the Roche Group, holding positions of increasing responsibility, including Senior Vice President, Global Head of Product Development for Immunology, Infectio Disease and Ophthalmology from 2018 to 2020, and was accountable for late stage clinical development of many products. Prior to entering industry, Dr. Eisner was Professor of Medicine and Anesthesia at the University of California, San Francisco. Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also holds an M.P.H. focused on epidemiology from the University of California, Berkeley, School of Public Health.- Mark Eisner于2023年9月至2024年6月在私营临床阶段生物技术公司Sonoma Biotherapeutics，Inc.担任首席医疗官，领导所有开发职能，包括生物识别、监管、临床科学、临床运营、药物安全和药理学。2020年至2023年9月，他在生物制药公司珐博进公司（nka Kyntra Bio，Inc.）（纳斯达克：KYNB）担任执行副总裁兼首席医疗官，领导所有开发职能，包括担任中国临床开发和临床运营主管。在加入珐博进之前，Eisner博士在罗氏集团成员基因泰克工作了近11年，担任的职位责任越来越大，包括2018年至2020年的高级副总裁、免疫学、感染病和眼科产品开发全球主管，并负责许多产品的后期临床开发。在进入工业之前，艾斯纳博士是加州大学旧金山分校的医学和麻醉学教授。艾斯纳博士在斯坦福大学完成了人类生物学的A.B.学位，并在宾夕法尼亚大学医学院完成了医学博士学位。他还拥有加州大学伯克利分校公共卫生学院流行病学硕士学位。
- Mark Eisner served as Chief Medical Officer at Sonoma Biotherapeutics, Inc., a private clinical stage biotechnology company, from September 2023 to June 2024, where he led all development functions, which included Biometrics, Regulatory, Clinical Science, Clinical Operations, Drug Safety and Pharmacology. From 2020 to September 2023, he served as Executive Vice President, Chief Medical Officer at FibroGen, Inc. (nka Kyntra Bio, Inc.) (Nasdaq: KYNB), a biopharmaceutical company, where he led all development functions, which included being the Head of China Clinical Development and Clinical Operations. Prior to FibroGen, Dr. Eisner spent nearly 11 years at Genentech, Inc., a member of the Roche Group, holding positions of increasing responsibility, including Senior Vice President, Global Head of Product Development for Immunology, Infectio Disease and Ophthalmology from 2018 to 2020, and was accountable for late stage clinical development of many products. Prior to entering industry, Dr. Eisner was Professor of Medicine and Anesthesia at the University of California, San Francisco. Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also holds an M.P.H. focused on epidemiology from the University of California, Berkeley, School of Public Health.
- Vanina de Verneuil
Vanina de Verneuil，Vir Biotechnology, Inc.执行副总裁、总法律顾问和公司秘书（2023 –至今），在此之前担任过多个职责日益增加的职位，包括高级副总裁、法律和公司秘书（2023）、公司法高级副总裁和临时总法律顾问，以及公司法副总裁（2020 – 2023）、合伙人、DLA Piper（2018 – 2019）、Reliance Communications/Global Cloud XChange全球总法律顾问（2014 – 2018）.B.A.，心理学和法语，杜克大学，法学博士，纽约大学法学院。
Vanina de Verneuil,Executive Vice President, General Counsel and Corporate Secretary, Vir Biotechnology, Inc. (2023 – present), and preceded by various positions of increasing responsibility, including Senior Vice President, Legal and Corporate Secretary (2023), Senior Vice President, Corporate Law and Interim General Counsel, and Vice President, Corporate Law (2020 – 2023),Partner, DLA Piper (2018 – 2019),Global General Counsel, Reliance Communications/Global Cloud Xchange (2014 – 2018).B.A., Psychology and French, Duke University,J.D., New York University School of Law.- Vanina de Verneuil，Vir Biotechnology, Inc.执行副总裁、总法律顾问和公司秘书（2023 –至今），在此之前担任过多个职责日益增加的职位，包括高级副总裁、法律和公司秘书（2023）、公司法高级副总裁和临时总法律顾问，以及公司法副总裁（2020 – 2023）、合伙人、DLA Piper（2018 – 2019）、Reliance Communications/Global Cloud XChange全球总法律顾问（2014 – 2018）.B.A.，心理学和法语，杜克大学，法学博士，纽约大学法学院。
- Vanina de Verneuil,Executive Vice President, General Counsel and Corporate Secretary, Vir Biotechnology, Inc. (2023 – present), and preceded by various positions of increasing responsibility, including Senior Vice President, Legal and Corporate Secretary (2023), Senior Vice President, Corporate Law and Interim General Counsel, and Vice President, Corporate Law (2020 – 2023),Partner, DLA Piper (2018 – 2019),Global General Counsel, Reliance Communications/Global Cloud Xchange (2014 – 2018).B.A., Psychology and French, Duke University,J.D., New York University School of Law.
- Marianne De Backer
Marianne De Backer，Vir Biotechnology, Inc.总裁兼首席执行官（2023 –至今），执行委员会，以及执行副总裁兼制药部门战略、业务发展和许可全球主管（2019 – 2023），拜耳公司，多个职责日益增加的职位，包括制药集团并购运营和资产剥离副总裁以及传染病和疫苗业务发展主管，强生（1991 – 2019），在欧洲领导商业业务部门以及在欧洲和美国从事药物发现研究的额外经验。布鲁塞尔自由大学分子生物学硕士，根特大学工程和生物化学硕士，根特大学生物技术博士，MBA，鹿特丹伊拉斯谟大学。
Marianne De Backer,President and Chief Executive Officer, Vir Biotechnology, Inc. (2023 – Present),Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing, Pharmaceuticals Division, Bayer AG (2019 – 2023),Various positions of increasing responsibility, including Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and Head of Infectious Diseases & Vaccines Business Development, Johnson & Johnson (1991 – 2019),Additional experience leading commercial business unit in Europe, as well as drug discovery research in both Europe and the United States.M.Sc., Molecular Biology, Vrije Universiteit Brussel,M.Sc., Engineering and Biochemistry, Ghent University,Ph.D., Biotechnology, Ghent University,MBA, Erasmus University Rotterdam.- Marianne De Backer，Vir Biotechnology, Inc.总裁兼首席执行官（2023 –至今），执行委员会，以及执行副总裁兼制药部门战略、业务发展和许可全球主管（2019 – 2023），拜耳公司，多个职责日益增加的职位，包括制药集团并购运营和资产剥离副总裁以及传染病和疫苗业务发展主管，强生（1991 – 2019），在欧洲领导商业业务部门以及在欧洲和美国从事药物发现研究的额外经验。布鲁塞尔自由大学分子生物学硕士，根特大学工程和生物化学硕士，根特大学生物技术博士，MBA，鹿特丹伊拉斯谟大学。
- Marianne De Backer,President and Chief Executive Officer, Vir Biotechnology, Inc. (2023 – Present),Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing, Pharmaceuticals Division, Bayer AG (2019 – 2023),Various positions of increasing responsibility, including Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and Head of Infectious Diseases & Vaccines Business Development, Johnson & Johnson (1991 – 2019),Additional experience leading commercial business unit in Europe, as well as drug discovery research in both Europe and the United States.M.Sc., Molecular Biology, Vrije Universiteit Brussel,M.Sc., Engineering and Biochemistry, Ghent University,Ph.D., Biotechnology, Ghent University,MBA, Erasmus University Rotterdam.
- Jason O byrne
Jason O'Byrne，Vir Biotechnology, Inc.执行副总裁兼首席财务官（2024 –至今），Caribou Biosciences, Inc.（2021 – 2024年），TERM3（Caribou Biosciences，Inc）TERM3（2021 – 2024年），财务高级副总裁，Audentes Therapeutics, Inc.（2020-2021年），Audentes Therapeutics, Inc.（2019-2020年），财务副总裁，TERM5（2019-2020年），担任的多个职位责任日益增加，包括罗氏亚太副总裁、财务主管，以及产品开发和产品战略副总裁、财务全球主管，基因泰克（2005 – 2018年）B.A.S.C.，不列颠哥伦比亚大学机械工程，MBA，金融，纽约大学斯特恩商学院。
Jason O byrne, Executive Vice President and Chief Financial Officer, Vir Biotechnology, Inc. (2024 – present),Chief Financial Officer, Caribou Biosciences, Inc. (2021 – 2024),Senior Vice President of Finance, Audentes Therapeutics, Inc. (2020-2021),Vice President of Finance, Audentes Therapeutics, Inc. (2019-2020),Various positions of increasing responsibility, including Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy, Genentech, Inc. (2005 – 2018).B.A.Sc., Mechanical Engineering, University of British Columbia,MBA, Finance, New York University's Stern School of Business.- Jason O'Byrne，Vir Biotechnology, Inc.执行副总裁兼首席财务官（2024 –至今），Caribou Biosciences, Inc.（2021 – 2024年），TERM3（Caribou Biosciences，Inc）TERM3（2021 – 2024年），财务高级副总裁，Audentes Therapeutics, Inc.（2020-2021年），Audentes Therapeutics, Inc.（2019-2020年），财务副总裁，TERM5（2019-2020年），担任的多个职位责任日益增加，包括罗氏亚太副总裁、财务主管，以及产品开发和产品战略副总裁、财务全球主管，基因泰克（2005 – 2018年）B.A.S.C.，不列颠哥伦比亚大学机械工程，MBA，金融，纽约大学斯特恩商学院。
- Jason O byrne, Executive Vice President and Chief Financial Officer, Vir Biotechnology, Inc. (2024 – present),Chief Financial Officer, Caribou Biosciences, Inc. (2021 – 2024),Senior Vice President of Finance, Audentes Therapeutics, Inc. (2020-2021),Vice President of Finance, Audentes Therapeutics, Inc. (2019-2020),Various positions of increasing responsibility, including Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy, Genentech, Inc. (2005 – 2018).B.A.Sc., Mechanical Engineering, University of British Columbia,MBA, Finance, New York University's Stern School of Business.